Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts
Reasons To Buy
What was the size of the United Kingdom biotechnology market by value in 2016?
What will be the size of the United Kingdom biotechnology market in 2021?
What factors are affecting the strength of competition in the United Kingdom biotechnology market?
How has the market performed over the last five years?
What are the main segments that make up the United Kingdom's biotechnology market?
The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
The UK biotechnology market is expected to generate total revenues of $10.4bn in 2016, representing a compound annual growth rate (CAGR) of 5.7% between 2012 and 2016.
The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $6.9bn, equivalent to 66% of the market's overall value.
In 2015 the investment into UK biotechnology reached a 10 year high, helping narrow the funding gap to the United States having previously lost highly promising biotech start-ups to New York.
Market value forecast
Market value forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Related MarketLine research
Figure 1: United Kingdom biotechnology industry value: $ million, 2012-16(e)
Figure 2: United Kingdom biotechnology industry category segmentation: % share, by value, 2016(e)
Figure 3: United Kingdom biotechnology industry geography segmentation: % share, by value, 2016(e)
Figure 4: United Kingdom biotechnology industry value forecast: $ million, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in the United Kingdom, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in the United Kingdom, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in the United Kingdom, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in the United Kingdom, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in the United Kingdom, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in the United Kingdom, 2016
Figure 11: AstraZeneca PLC: revenues & profitability
Figure 12: AstraZeneca PLC: assets & liabilities
Figure 13: Novartis AG: revenues & profitability
Figure 14: Novartis AG: assets & liabilities
Figure 15: Sanofi SA: revenues & profitability
Figure 16: Sanofi SA: assets & liabilities
Table 1: United Kingdom biotechnology industry value: $ million, 2012-16(e)
Table 2: United Kingdom biotechnology industry category segmentation: $ million, 2016(e)
Table 3: United Kingdom biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: United Kingdom biotechnology industry value forecast: $ million, 2016-21
Table 5: AstraZeneca PLC: key facts
Table 6: AstraZeneca PLC: key financials ($)
Table 7: AstraZeneca PLC: key financial ratios
Table 8: GE Healthcare: key facts
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (EUR)
Table 15: Sanofi SA: key financial ratios
Table 16: United Kingdom size of population (million), 2012-16
Table 17: United Kingdom gdp (constant 2005 prices, $ billion), 2012-16
Table 18: United Kingdom gdp (current prices, $ billion), 2012-16
Table 19: United Kingdom inflation, 2012-16
Table 20: United Kingdom consumer price index (absolute), 2012-16
Table 21: United Kingdom exchange rate, 2012-16
Single User License:
Corporate User License:
AstraZeneca PLC GE Healthcare Novartis AG Sanofi SA
Biotechnology, MarketLine, United Kingdom
select a license
NEWSLETTER BY CATEGORY
An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ... "General Manager SBU Manufacture, PT. KIMIA FARMA, TBK"
Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process.... "VP Innovation, Engineered Profiles LLC"
Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed... "President, VPP E-Data Services, VPP E-Data Services"
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"
This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"